Improvement of cerebral blood flow by olprinone, a phosphodiesterase-3 inhibitor, in mild heart failure

Cerebrovascular Diseases

Volumn 16, Issue 4, 2003, Pages 396-401

  Ueda, Takashi ^a   Mizushige, Katsufumi ^b   Yukiiri, Kazushi ^b   Takahashi, Tsutomu ^b   Kohno, Masakazu ^b  

^a Ueda Naika Clinic   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Cerebral blood flow; Heart failure; Olprinone; Phosphodiesterase 3 inhibitor

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIOTONIC AGENT; CYSTEINE ETHYL ESTER TC 99M; DIGITALIS; DIURETIC AGENT; LOPRINONE; PHOSPHODIESTERASE INHIBITOR; VASOACTIVE AGENT;

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN INFARCTION; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; MALE; PRIORITY JOURNAL; SCINTIANGIOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PYRIDONES; SEVERITY OF ILLNESS INDEX;

EID: 0141676272     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072563     Document Type: Article

References (19)

1. Gruhn N, Larsen F, Boesgaard S, Kundsen GM, Mortensen SA, Thomsen G, Aldershvile J: Cerebral blood flow in patients with chronic heart failure before and after heart transplantation. Stroke 2001;32:2530-2533.
2. Boume GJ, Muizelaar P: Relationship between cardiac output and cerebral blood flow in patients with intact and with impaired autoregulation. J Neurosurg 1990;73:368-374.
3. Georgiadis SD, Cencetti S, Uhlmann F, Krivokuca M, Zierz S, Werdan K: Cerebrovascular reactivity is impaired in patients with cardiac failure. Eur Heart J 2000;21:407-413.
4. Roman DD, Kubo SH, Ormaza S, Francis GS, Bank AJ, Shumway SJ: Memory improvement following cardiac transplantation. J Clin Exp Neuropsychol 1997;19:692-697.
5. Zuccala G, Cattel C, Manes-Gravina E, Di Niro MG, Cocchi A, Bervabei R: Left ventricular dysfunction: A clue to cognitive impairment in older patients with heart failure. J Neurol Neurosurg Psychiatry 1997;63:509-512.
6. Yukiiri K, Mizushige K, Ueda T, Nishiyama Y, Aoyama T, Kohno M: Effects of olprinone, a phosphodiesterase 3 inhibitor, on regional cerebral blood flow of cerebral cortex in stroke patients. J Cardiovasc Pharmacol 2001;37:375-380.
7. Yu Y, Mizushige K, Ueda T, Nishiyama Y, Seki M, Aoyama T, Ohkawa M, Matsuo H: Effect of olprinone, phosphodiesterase III inhibitor, on cerebral blood flow assessed with technetium-99m-ECD SPECT. J Cardiovasc Pharmacol 2000;35:422-426.
8. Takeuchi R, Matsuda H, Yonekura Y, Sakahara H, Konishi J: Noninvasive quantitative measurements of regional cerebral blood flow using technetium-99m-L, L-ECD SPECT activated with acetazolamide: Quantification analysis by equal-volume-split 99mTc-ECD consecutive SPECT method. J Cereb Blood Flow Metab 1997;17:1020-1032.
9. Wanless RB, Anand IS, Gurden J, Harris P, Poole-Wilson PA: Regional blood flow and hemodynamics in the rabbit with adriamycin cardiomyopathy: Effects of isosorbide dinitrate, dobutamine and captopril. J Pharmacol Exp Ther 1987;243:1101-1106.
10. Nakane H, Ibayashi S, Fujii K, Sadoshima S, Irie K, Kitazono T, Fujishima M: Cerebral blood flow and metabolism in patients with silent brain infarction: Occult misery perfusion in the cerebral cortex. J Neurol Neurosurg Psychiatry 1998;65:317-321.
11. i and force in middle cerebral artery of the rabbit. Br J Pharmacol 1998. 123; 869-878.
12. Fujimoto S, Ohashi M, Hiramoto A, Inoue Y, Nagai K, Shiokawa H, Itoh T: Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits. Eur J Pharmacol 1998;353:239-246.
13. Onoue H, Katusic ZS: The effect of subarachnoid hemorrhage on mechanisms of vasodilation mediated by cyclic adenosine monophosphate. J Neurosurg 1998;89:111-117.
14. Lee CW, Lee JH, Lim T-H, Yang HS, Hong M-K, Song JK, Park S-W, Park S-J, Kim J-J: Prognostic significance of cerebral metabolic abnormalities in patients with congestive heart failure. Circulation 2001;103:2784-2787.
15. Ross B, Michaelis T: Clinical application of magnetic resonance spectroscopy. Magn Reson Q 1994;10:191-247.
16. Harvey BH, Carstens ME, Taljaard JJF: Central effects of the preservative, methylparaben. In vivo activation of cAMP-specific phosphodiesterase and reduction of cortical cAMP. Biochem Pharmacol 1992;44:1053-1057.
17. Nicholson CD, Challiss RAJ, Shahid M: Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isozymes. Trends Pharmacol Sci 1991;12:19-27.
18. Challis RAJ, Nicholson CD: Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices. Br J Pharmacol 1990;52:47-52.
19. Sasayama S, Asanoi H, Kihara Y, Yokawa S, Terada Y, Yoshida S, Ejiri M, Horikoshi I: Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 1994;9:113-121.